Upper GI

Achalasia

Achalasia is a primary esophageal motility disorder characterized by failure of the lower esophageal sphincter to relax and absent peristalsis in the esophageal body due to degeneration of inhibitory neurons in the myenteric plexus.

Achalasia

Anatomy & Functional Review

To understand achalasia, you need to understand normal oesophageal swallowing physiology from first principles.

Aetiology

Pathophysiology — Detailed

Let's walk through the pathophysiological cascade from the molecular level to the clinical presentation:

Classification

Clinical Features

Differential Diagnosis of Achalasia

When a patient walks in with dysphagia ± regurgitation ± chest pain, your job is to systematically work through the differentials. The key clinical reasoning pivot is: Is this a motility (functional) problem or a structural (mechanical) problem? And if it looks like achalasia on manometry, is it true primary achalasia or something mimicking it?

Let's break this down from first principles.


Category 1: Conditions That Mimic Achalasia Symptoms

References

[1] Lecture slides: GC 189. I can't swallow oesophageal cancer.pdf [2] Senior notes: maxim.md (Section 3.4 — Achalasia) [3] Senior notes: felixlai.md (Section: Achalasia) [4] Senior notes: maxim.md (Section 3.5 — CA esophagus) [5] Senior notes: maxim.md (Section 3.2 — Dysphagia) [6] Senior notes: maxim.md (Section: Zenker's diverticulum)

Diagnostic Criteria, Algorithm & Investigations for Achalasia

Diagnostic Criteria

There is no single "checklist" diagnostic criterion for achalasia like there is for, say, rheumatic fever. Instead, the diagnosis rests on demonstrating the characteristic manometric triad while excluding mechanical obstruction and pseudoachalasia. Let's build this from first principles.

Investigation Modalities: Detailed Breakdown

References

[2] Senior notes: maxim.md (Section 3.4 — Achalasia) [3] Senior notes: felixlai.md (Section: Achalasia, Section VI. Diagnosis) [5] Senior notes: maxim.md (Section 3.2 — Dysphagia)

Management of Achalasia

Treatment Modalities — Detailed Breakdown

A. Pharmacological / Temporising Treatments

These are NOT definitive treatments. They provide temporary symptom relief and are reserved for patients who cannot undergo more effective interventions.


B. Definitive Treatments — Mechanical Disruption of the LES

These are the treatments that actually produce durable symptom relief. The fundamental principle is the same across all three: physically disrupt (tear or cut) the circular muscle fibres of the LES so the sphincter can no longer maintain its hypertonic contraction.


Head-to-Head Comparison of Definitive Treatments

Comparison of treatments [2]:

FeaturePneumatic DilationHeller Myotomy + DorPOEM
ApproachEndoscopic (balloon)Laparoscopic (surgical)Endoscopic (submucosal tunnel)
AnaesthesiaSedation ± GAGeneral anaesthesiaGeneral anaesthesia
Efficacy (short-term)65–85%≥ 90%90–95%
Efficacy (long-term)Lower; may need repeatExcellent; durableExcellent; still accumulating long-term data
Overall effectivenessGoodMyotomy (endoscopic/surgical) most effective [2]Most effective [2]
Anti-reflux mechanismNone (but less mucosal disruption)Partial fundoplication (Dor 180°)None → more reflux [2]
Post-op GERD rate~15–35%~10–20% (protected by Dor)Higher (~40–50%) [2] → needs PPI
Post-op dysphagiaRareMore dysphagia [2] (from fundoplication)Less dysphagia
Hospital stayDay case / overnight2–3 daysFewer hospital days [2]; 1–2 days
For Type IIIPoor responseModerate (limited myotomy length)Best option (can extend myotomy)
RepeatabilityYes (graded dilation)Redo myotomy difficultCan be done after prior Heller
Perforation risk2–5%~5% (mucosal injury)~2%

How to Choose? A Pragmatic Approach

Type I or II achalasia in a fit patient: All three definitive options are reasonable. Current evidence (2020 POET trial, European Achalasia Trial) suggests Heller myotomy and POEM have similar efficacy; PD is slightly less durable but is less invasive. Shared decision-making with the patient is key.

Type III achalasia: POEM preferred because only POEM can extend the myotomy along the entire spastic oesophageal body.

Elderly or high surgical risk: Graded PD (less invasive) or Botox injection.

Failed PD: Heller myotomy or POEM.

Failed Heller: POEM (can find a new submucosal plane).

End-stage sigmoid oesophagus (decompensated): Oesophagectomy may be the only option — the oesophagus is so dilated and tortuous that myotomy/dilation cannot improve emptying.


References

[2] Senior notes: maxim.md (Section 3.4 — Achalasia, Management) [3] Senior notes: felixlai.md (Section: Achalasia, Section VII. Treatment) [7] Senior notes: maxim.md (Section: GERD — Surgical treatment, fundoplication types) [8] Senior notes: felixlai.md (Section: Dysphagia, Section V. Treatment — General management)

Complications of Achalasia

Complications of achalasia can be divided into two categories: (A) complications of the disease itself (from chronic oesophageal stasis and dilation) and (B) complications of treatment (from the interventions used to manage it). Let's work through each from first principles, linking every complication back to its pathophysiological basis.


A. Complications of the Disease

The root cause of all disease-related complications is the same: functional obstruction at the LES + aperistalsis → chronic food stasis → progressive oesophageal dilation. Everything else follows.


B. Complications of Treatment

Each treatment modality carries specific complications, directly related to its mechanism of action.


References

[2] Senior notes: maxim.md (Section 3.4 — Achalasia, Complications and Management) [3] Senior notes: felixlai.md (Section: Achalasia — Overview, Clinical manifestations) [4] Senior notes: maxim.md (Section 3.5 — CA esophagus, Risk factors) [7] Senior notes: maxim.md (Section: GERD — Surgical treatment, fundoplication complications) [9] Senior notes: maxim.md (Section 3.5 — CA esophagus, Epidemiology)

High Yield Summary

Definition: Achalasia = failure of LES relaxation + aperistalsis of oesophageal body due to degeneration of inhibitory neurons (NO/VIP) in the myenteric plexus.

Triad on manometry: (1) Aperistalsis, (2) Elevated basal LES pressure, (3) Impaired LES relaxation on swallowing.

Epidemiology: Equal sex ratio, peak 35–45 years, ~1–3/100,000/year.

Aetiology: Primary (idiopathic, >90%) vs secondary (Chagas disease, pseudoachalasia from malignancy, infiltrative disorders). Always exclude pseudoachalasia with OGD ± EUS.

Chicago Classification: Type I (minimal pressurisation), Type II (pan-oesophageal pressurisation — best prognosis), Type III (spastic — worst prognosis).

Cardinal symptoms: Progressive dysphagia to solids AND liquids (100%), regurgitation of undigested food (70%), chest pain, heartburn (from fermentation, NOT acid reflux), difficulty belching, weight loss.

Red flags for pseudoachalasia: Age > 60, short symptom duration, rapid weight loss, difficulty passing scope through GOJ.

Complication: Oesophageal SCC (long-term); aspiration pneumonia; malnutrition.

HK relevance: Primary achalasia is dominant; achalasia is a risk factor for oesophageal SCC (most common oesophageal cancer in HK); Chagas disease not relevant locally.

High Yield Summary

Three categories of differentials for achalasia:

  1. Symptom mimics: GERD (heartburn + regurgitation — distinguish by PPI response and manometry), oesophageal cancer (progressive solids → liquids — distinguish by OGD), peptic stricture, EoE

  2. Manometric mimics (pseudoachalasia): Same manometric findings as achalasia. Caused by malignancy invading the neural plexus or paraneoplastic syndrome. Red flags: age > 60, short history, rapid weight loss, shouldering on barium swallow. Always OGD ± EUS before diagnosing primary achalasia.

  3. Other motility disorders: DES and Jackhammer oesophagus have normal IRP on manometry (LES relaxation is preserved) — this is the key distinguishing feature. Scleroderma has absent peristalsis but low LES pressure (opposite of achalasia).

Key investigation: High-resolution manometry (HRM) is the definitive diagnostic tool. IRP ≥ 15 mmHg = achalasia (or pseudoachalasia). Normal IRP = not achalasia, consider DES/Jackhammer/other.

High Yield Summary

Definitive diagnosis = High-Resolution Manometry (HRM) showing the triad: (1) IRP ≥ 15 mmHg, (2) absent normal peristalsis, (3) elevated basal LES pressure. Chicago Classification v4.0 subtypes based on oesophageal body pattern: Type I (minimal pressurisation), Type II (pan-oesophageal pressurisation — best prognosis), Type III (spastic — worst prognosis).

OGD is mandatory FIRST to exclude pseudoachalasia and assess complications. Up to 40% of achalasia patients have normal OGD — a normal scope does NOT exclude achalasia. Typical findings: dilated oesophagus with food residue, tight cardia that opens with gentle pressure.

Barium swallow: bird's beak sign (smooth tapering at LES), proximal dilation, sigmoid oesophagus in late disease. Shouldering/heaping = pseudoachalasia red flag. Usually not done now as primary diagnostic tool.

CXR: widened mediastinum + absent gastric bubble (air cannot enter stomach through non-relaxing LES).

EUS: for pseudoachalasia workup — characterise EGJ tumours. In primary achalasia shows thickened circular muscle layer.

Contrast safety: Barium — avoid if perforation risk (barium peritonitis). Gastrografin — avoid if aspiration risk (chemical pneumonitis). Omnipaque — safest if both risks present.

High Yield Summary

Principle: Treatment reduces LES pressure by pharmacological relaxation or mechanical disruption of muscle fibres. No treatment restores lost neurons or normalises swallowing.

Pharmacological (temporising only):

  • Botox injection: blocks ACh release → reduces LES tone; for patients unfit for definitive therapy; temporary (6–12 months); causes fibrosis complicating future surgery.
  • Nitrates/CCB: least effective; sublingual nifedipine or ISDN before meals; last resort.

Definitive treatments:

  • Graded Pneumatic Dilation: disrupts LES muscle fibres; curative in 65–85%; main risk = perforation (2–5%).
  • Laparoscopic Heller Myotomy + Dor fundoplication: ≥ 90% success; partial anterior wrap prevents GERD without causing dysphagia in aperistaltic oesophagus; more dysphagia than POEM.
  • POEM: endoscopic myotomy via submucosal tunnel; ~90–95% success; preferred for Type III achalasia (can extend myotomy along spastic body); shorter hospital stay; higher reflux rate (no fundoplication → needs PPI).

Treatment selection by subtype: Type I/II → any definitive option; Type III → POEM preferred; elderly/unfit → PD or Botox; end-stage → oesophagectomy.

Treatment relieves dysphagia but NOT chest pain — counsel patients accordingly.

High Yield Summary

Disease complications — all stem from chronic food stasis in a dilated, aperistaltic oesophagus above a non-relaxing LES:

  • Mucosal: erosions, candida oesophagitis (stasis + irritation)
  • Respiratory: aspiration pneumonia (regurgitated stagnant food into airway)
  • Structural: lower oesophageal diverticula (raised intraluminal pressure), sigmoid megaoesophagus (end-stage)
  • Malignancy: oesophageal SCC (~30× risk; develops after 15–25 years; needs long-term OGD surveillance)

Treatment complications — specific to modality:

  • PD: perforation (2–5%), GERD
  • Heller myotomy: mucosal perforation, dysphagia from fundoplication (50% early, 10% long-term), GERD
  • POEM: GERD (40–50% — the major disadvantage; no fundoplication → needs PPI), mediastinitis, surgical emphysema
  • Botox: submucosal fibrosis (complicates future myotomy)

Cancer risk: Achalasia is a recognised risk factor for oesophageal SCC. Surveillance with periodic OGD recommended from 10–15 years post-diagnosis.

On this page

No Headings